12/01-2017 08:45:14: (SEZI.ST) Senzime: Senzime reports completion of trial
Uppsala, January 12, 2017. Senzime AB (publ) reports completion of the initial volunteer study performed at the Mayo Clinic in the USA. The study evaluated the ease of use, required set-up time, and volunteer comfort during testing using Senzime.s patient neuromonitoring system, the TetraGraph.
Senzime, in collaboration with the principal investigator Dr. J. Ross Renew, a recognized researcher in the area of neuromuscular pharmacology and physiology at Mayo Clinic.s Florida USA location in Jacksonville carried out a validation study in volunteers to evaluate TetraGraph.s ease of use, required set-up time, and the discomfort associated with neurostimulation. The TetraGraph was compared with the existing monitor based on acceleromyography, the TOF-Watch.
Every year over 70 million surgical patients undergo general anesthesia and receive neuromuscular blocking drugs. Without objective monitoring, over 30 percent of these patients experience postoperative complications. The TetraGraph monitor is a portable and user-friendly EMG-based device that allows quantitative neuromuscular monitoring in settings where motion detection is not possible.
.Ease of use in conjunction with the current increasing trend to demand objective neuromuscular monitoring in patients who receive muscle relaxant drugs which is now becoming standard of practice in several countries, will definitively contribute to increase usage and patient safety, as well as shorten hospital stay. TetraGraph will play a major role in surgical procedures in the future" says Senzime.s CEO, Lena Söderström.
Study results will be available following peer reviewed publication in a medical journal.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients. neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com
Ekstern link: http://www.aktietorget.se/NewsItem.aspx?ID=81709
Ekstern link: https://press.aktietorget.se/Senzime/81709/613361.pdf
Nyheten er levert av Aktietorget.